Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Agile Therapeutics, Inc. (AGRX)

1.805   -0.015 (-0.82%) 09-21 10:54
Open: 1.97 Pre. Close: 1.82
High: 1.97 Low: 1.75
Volume: 19,606 Market Cap: 3(M)

Technical analysis

as of: 2023-09-21 10:44:25 AM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 2.69     One year: 3.07
Support: Support1: 1.78    Support2: 1.48
Resistance: Resistance1: 2.3    Resistance2: 2.63
Pivot: 2.16
Moving Average: MA(5): 1.91     MA(20): 2.15
MA(100): 3.18     MA(250): 8.34
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 2.8     %D(3): 4.7
RSI: RSI(14): 32.9
52-week: High: 16  Low: 1.78
Average Vol(K): 3-Month: 48 (K)  10-Days: 38 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AGRX ] has closed above bottom band by 13.9%. Bollinger Bands are 19.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.9 - 1.91 1.91 - 1.92
Low: 1.76 - 1.78 1.78 - 1.79
Close: 1.8 - 1.82 1.82 - 1.84

Company Description

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Headline News

Tue, 05 Sep 2023
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference -

Tue, 05 Sep 2023
Agile Therapeutics to Present at the H.C. Wainwright 25th - GlobeNewswire

Thu, 31 Aug 2023
Should You Buy Agile Therapeutics Inc (AGRX) Stock After it Has Gained 17.31% in a Week? - InvestorsObserver

Fri, 11 Aug 2023
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript - Yahoo Finance

Wed, 09 Aug 2023
Agile Therapeutics, Inc. (AGRX) Q2 2023 Earnings Call Transcript - Seeking Alpha

Wed, 26 Jul 2023
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023 - Yahoo Finance

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 2 (M)
Shares Float 2 (M)
% Held by Insiders 3.4 (%)
% Held by Institutions 1 (%)
Shares Short 21 (K)
Shares Short P.Month 71 (K)

Stock Financials

EPS 155.22
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -7.39
Profit Margin (%) -116.9
Operating Margin (%) -161.2
Return on Assets (ttm) -72.5
Return on Equity (ttm) 0
Qtrly Rev. Growth 158.8
Gross Profit (p.s.) 0
Sales Per Share 8.45
EBITDA (p.s.) -13.35
Qtrly Earnings Growth 0
Operating Cash Flow -28 (M)
Levered Free Cash Flow -20 (M)

Stock Valuations

PE Ratio 0.01
PEG Ratio 0
Price to Book value -0.25
Price to Sales 0.21
Price to Cash Flow -0.13

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.